Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung × lazertinib × Clear all

NCT07586202 2026-05-14

AmiNA

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT02609776 2026-05-08

CHRYSALIS

Phase 1 Active not recruiting

751 enrolled 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT04077463 2026-05-08

Chrysalis-2

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04487080 2026-05-08

MARIPOSA

Phase 3 Active not recruiting

1,074 enrolled 13 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT04988295 2026-05-08

MARIPOSA-2

Phase 3 Active not recruiting

776 enrolled 13 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT05388669 2026-05-08

PALOMA-3

Phase 3 Active not recruiting

418 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT05498428 2026-05-08

PALOMA-2

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06120140 2026-05-08

COCOON

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06667076 2026-05-08

COPERNICUS

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05663866 2026-04-13

Premedication to Reduce Amivantamab Associated Infusion Related Reactions

Phase 2 Active not recruiting

68 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT06268210 2026-02-09

NeoLazer

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05786430 2026-01-27

LUCAS

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05601973 2026-01-21

AMAZE-lung

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04965090 2025-12-18

A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT04075396 2025-04-29

A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 1/2 Completed

29 enrolled 53 charts

Carcinoma, Non-Small-Cell Lung

NCT04248829 2024-12-03

Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

Phase 3 Active not recruiting

393 enrolled 13 charts

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

NCT05338619 2023-09-01

PLATINUM

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT06020989 2023-09-01

CHAMELEON

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05862194 2023-08-22

Retrospective, External Comparator Study of Lazertinib as the 2nd-Line Treatment in Patients With EGFR Mutation+ NSCLC

Carcinoma, Non-Small-Cell Lung

NCT05716672 2023-02-08

Impact of Lazertinib Dose Modification on Effectiveness and Safety

Carcinoma, Non-Small-Cell Lung

NCT05477615 2022-07-28

Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain Metastases

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05377788 2022-05-19

Lazertinib Real-world Observational Study of in Pre-treated EGFR T790M Mutant With Advanced Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

NCT05167851 2021-12-22

The Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung